Belluscura (BELL) Competitors GBX 0.60 -0.13 (-17.24%) As of 04/17/2025 11:13 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsBuy This Stock BELL vs. RUA, MHC, SUN, DEMG, NIOX, SN, MXCT, EKF, IUG, and CREOShould you be buying Belluscura stock or one of its competitors? The main competitors of Belluscura include RUA Life Sciences (RUA), MyHealthChecked (MHC), Surgical Innovations Group (SUN), Deltex Medical Group (DEMG), NIOX Group (NIOX), Smith & Nephew (SN), MaxCyte (MXCT), EKF Diagnostics (EKF), Intelligent Ultrasound Group (IUG), and Creo Medical Group (CREO). These companies are all part of the "medical devices" industry. Belluscura vs. RUA Life Sciences MyHealthChecked Surgical Innovations Group Deltex Medical Group NIOX Group Smith & Nephew MaxCyte EKF Diagnostics Intelligent Ultrasound Group Creo Medical Group RUA Life Sciences (LON:RUA) and Belluscura (LON:BELL) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations, community ranking and profitability. Is RUA or BELL more profitable? RUA Life Sciences has a net margin of -65.72% compared to Belluscura's net margin of -1,030.73%. RUA Life Sciences' return on equity of -26.38% beat Belluscura's return on equity.Company Net Margins Return on Equity Return on Assets RUA Life Sciences-65.72% -26.38% -17.50% Belluscura -1,030.73%-102.62%-43.53% Does the media refer more to RUA or BELL? In the previous week, RUA Life Sciences' average media sentiment score of 0.00 equaled Belluscura'saverage media sentiment score. Company Overall Sentiment RUA Life Sciences Neutral Belluscura Neutral Do institutionals & insiders have more ownership in RUA or BELL? 26.0% of RUA Life Sciences shares are held by institutional investors. Comparatively, 6.3% of Belluscura shares are held by institutional investors. 51.3% of RUA Life Sciences shares are held by insiders. Comparatively, 56.3% of Belluscura shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community favor RUA or BELL? RUA Life Sciences and Belluscura both received 0 outperform votes by MarketBeat users. CompanyUnderperformOutperformRUA Life SciencesOutperform VotesNo VotesUnderperform Votes6100.00% BelluscuraN/AN/A Which has more risk & volatility, RUA or BELL? RUA Life Sciences has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Belluscura has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Which has higher earnings & valuation, RUA or BELL? RUA Life Sciences has higher revenue and earnings than Belluscura. RUA Life Sciences is trading at a lower price-to-earnings ratio than Belluscura, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRUA Life Sciences£4.05M1.82-£2.66M-£4.29-2.76Belluscura£2.87M0.53-£29.55M-£9.37-0.06 SummaryRUA Life Sciences beats Belluscura on 9 of the 11 factors compared between the two stocks. Get Belluscura News Delivered to You Automatically Sign up to receive the latest news and ratings for BELL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BELL vs. The Competition Export to ExcelMetricBelluscuraMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£1.51M£3.03B£5.31B£2.51BDividend YieldN/A2.45%5.45%4.79%P/E Ratio-0.0663.5921.94130.40Price / Sales0.53113.75380.95234,760.40Price / Cash8.0015.9938.2628.32Price / Book0.053.646.454.43Net Income-£29.55M£126.02M£3.22B£5.89B1 Month Performance-62.50%-7.13%-9.76%-1.34%1 Year Performance-92.00%-13.44%11.49%41.47% Belluscura Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BELLBelluscuraN/AGBX 0.60-17.2%N/A-92.3%£1.51M£2.87M-0.0624Gap DownRUARUA Life SciencesN/AGBX 11.27+2.5%N/A+1.6%£6.99M£4.05M-2.6348Gap DownMHCMyHealthCheckedN/AGBX 13.20-5.7%N/A+27.2%£6.87M£9.43M-6.5816Gap DownSUNSurgical Innovations GroupN/AGBX 0.55+9.6%N/A-9.1%£5.11M£12.54M-21.1180Gap UpDEMGDeltex Medical GroupN/AN/AN/AN/A£187,000.00£1.76M-0.1537Gap UpHigh Trading VolumeNIOXNIOX Group2.4689 of 5 starsGBX 70.99+7.2%N/A-9.0%£29.16B£3.53B2,929.6392Analyst ForecastPositive NewsGap UpSNSmith & Nephew3.2974 of 5 starsGBX 991.60+1.2%GBX 4,607.50+364.7%+2.4%£10.87B£7.08B35.7018,452Gap UpHigh Trading VolumeMXCTMaxCyteN/AGBX 188.25+2.9%N/A-37.7%£248.50M£57.52M-6.9080News CoverageGap DownEKFEKF DiagnosticsN/AGBX 21.70+1.4%N/A-22.3%£96.45M£49.91M20.19356Gap UpIUGIntelligent Ultrasound GroupN/AN/AN/AN/A£42.76M£6.57M-18.9165CREOCreo Medical GroupN/AGBX 10.11-0.2%N/A-72.3%£40.85M£33.87M-1.60279 Related Companies and Tools Related Companies RUA Competitors MHC Competitors SUN Competitors DEMG Competitors NIOX Competitors SN Competitors MXCT Competitors EKF Competitors IUG Competitors CREO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:BELL) was last updated on 4/19/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belluscura plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belluscura With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BELL Stock Free BELL Stock Alerts